You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Indoco Remedies reported Q2 FY27 consolidated net revenue of Rs. 5,069 million, up 7.4%, with consolidated EBITDA of Rs. 464 million at 9.2% of net sales. International formulation revenue grew 12.1% to Rs. 1,720 million.
Illustrative technical + ownership context — a signal mix, not investment advice.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XNSE:INDOCO | +6.3% | -5.1% | +14.9% | +9.8% | -2.5% |
No verified company website is available for this listing yet.
Share classes and depositary receipts can have different prices and dividends.
| Ex-dividend date | Amount per share |
|---|---|
| 2026-09-10 | 0.20 INR |
| 2025-09-04 | 0.20 INR |
| 2024-09-19 | 1.50 INR |
| 2023-09-18 | 2.25 INR |
| 2022-09-14 | 2.25 INR |
| 2021-09-17 | 1.50 INR |
| 2020-09-18 | 0.30 INR |
| 2019-08-22 | 0.30 INR |
| 2018-08-31 | 1.00 INR |
| 2017-07-31 | 1.60 INR |
| 2016-07-20 | 0.20 INR |
| 2016-03-17 | 1.40 INR |
| 2015-07-21 | 1.60 INR |
| 2014-07-21 | 1.40 INR |
| 2013-07-19 | 1.10 INR |
| 2012-07-20 | 1.10 INR |
No upcoming investor events are listed for this company yet.
